Skip to main content

Table 3 Factors for predicting the overall survival

From: Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Factors   Median survival P-value
   (months)  
Age (yrs) ≤60 9.8 ± 4.9 0.585
  >60 13.6 ± 2.1  
Gender Male 12.9 ± 1.9 0.293
  Female 11.6 ± 1.0  
ECOG 1 15.9 ± 4.0 0.070
  2 9.8 ± 3.1  
Etiology Viral 11.3 ± 1.4 0.344
  Non-viral 13.6 ± 2.2  
Child-Pugh A 13.0 ± 1.5 0.309
Classification B 6.4 ± 0.8  
JIS score 2 13.0 ± 1.4 0.235
  3 5.8 ± 0.3  
Pretreatment ≤ 20 15.9 ± 1.6 0.161
AFP (ng/ml) > 20 10.9 ± 1.0  
Type of HCC Nodular 11.3 ± 0.7 0.853
  Diffuse infiltrative 13.6 ± 4.4  
Multiplicity Solitary 11.3 ± 1.3 0.534
  Multiple 13.9 ± 2.1  
Location of thrombi PV branch 16.6 ± 5.9 0.036
  Main portal trunk 9.8 ± 4.2  
BED (Gy10) < 75 13.0 ± 1.4 0.901
  ≥ 75 9.8 ± 4.7  
PVTT response CR + PR 13.9 ± 1.1 0.142
  SD + PD 6.9 ± 5.1  
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; JIS, Japan integrated staging; AFP, α-fetoprotein; HCC, Hepatocellular carcinoma; PV, Portal vein; BED, biologically effective dose; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
  2. P-values are obtained by log-rank test.